Pj Chen

Cali Biosciences is an international biopharmaceutical company dedicated to the research and development of innovative drugs. We have an international team of scientific research and management talents and is developing new drugs based on several patented technology platforms. We focus on the R&D of perioperative drugs. The product pipeline includes new drugs in the fields of anesthesia, analgesia, anti-inflammatory and anti-infection. In the future, we will also promote the commercialization of products to fully respond to the unmet market demand. The company focuses on the research and development of innovative drugs, with laboratories and offices in Shenzhen, China, and San Diego, USA, and a clinical development center in Shanghai, China. The company's main business is the R&D and production of innovative drugs, registration and application, as well as Sino-US market research, strategic operations and commercialization. The current product pipeline is consists of several modified new drugs based on the 505(b)(2) regulatory pathways. During the R&D process and upon completing the clinical trials, we seek approval from China, US and EU regulatory agencies and aiming at bringing innovative drugs in global markets. We are building a perioperative medication (anaesthesia, analgesia, anti-inflammatory, anti-infection) pipeline to meet the global unmet needs. At present, we have multiple clinical and pre-clinical stage drug candidates, the target market of the product pipeline is huge, and the clinical needs are clear. All the product pipeline is complex injection preparations with high technology patent threshold. Our goal is to serve patients and medical staff around the world, and our mission is to improve human survival and the quality of life.